The disclosure relates to a pharmaceutical pack for use in a method for treating a neoplasm in a subject, said pharmaceutical pack comprising a first compound selected from (E)-N-{ 4-[3-chloro-4-(2-pyridinylmethoxy) anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide, an ester, ether, carbamate or pharmaceutically acceptable salt thereof and a second compound selected from vinorelbine or a pharmaceutically acceptable salt thereof, wherein said first compound is in a unit dose and wherein the unit dose contains 50 to 300 mg of said first compound, wherein the first compound and the second compound may be administered concurrently, sequentially, simultaneously, in a specified order, or according to a specific temporal relationship, and wherein said neoplasm is selected from the group consisting of a lung cancer, breast cancer, myeloma, prostate cancer, head and neck cancer, transitional cell carcinoma, small cell neuroendocrine carcinoma of the uterine cervix, and large cell neuroendocrine carcinoma of the uterine cervix.
